View Item 

Show simple item record

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

dc.contributor.authorCrabb, David W.
dc.contributor.authorIm, Gene Y.
dc.contributor.authorSzabo, Gyongyi
dc.contributor.authorMellinger, Jessica L.
dc.contributor.authorLucey, Michael R.
dc.date.accessioned2020-02-05T15:03:46Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-02-05T15:03:46Z
dc.date.issued2020-01
dc.identifier.citationCrabb, David W.; Im, Gene Y.; Szabo, Gyongyi; Mellinger, Jessica L.; Lucey, Michael R. (2020). "Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases." Hepatology (1): 306-333.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/153536
dc.publisherWiley Periodicals, Inc.
dc.publisherWHO
dc.titleDiagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153536/1/hep30866_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153536/2/hep30866.pdf
dc.identifier.doi10.1002/hep.30866
dc.identifier.sourceHepatology
dc.identifier.citedreferenceSpahr L, Lambert JF, Rubbia‐Brandt L, Chalandon Y, Frossard JL, Giostra E, et al. Granulocyte‐colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology 2008; 48: 221 ‐ 229.
dc.identifier.citedreferenceYates WR, Booth BM, Reed DA, Brown K, Masterson BJ. Descriptive and predictive validity of a high‐risk alcoholism relapse model. J Stud Alcohol 1993; 54: 645 ‐ 651.
dc.identifier.citedreferenceDe Gottardi A, Spahr L, Gelez P, Morard I, Mentha G, Guillaud O, et al. A simple score for predicting alcohol relapse after liver transplantation. Arch Intern Med 2007; 167: 1183 ‐ 1188.
dc.identifier.citedreferenceBeresford TP. Psychiatric assessment. In: Lucey MR, Merion RM, Beresford TP, eds. Liver Transplantation and the Alcoholic Patient: Medical, Surgical and Psychosocial Issues. New York, NY: Cambridge University Press; 1994: 96 ‐ 112.
dc.identifier.citedreferenceSchaubel DE, Guidinger MK, Tome S, Merion RM. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology 2009; 50: 400 ‐ 406.
dc.identifier.citedreferenceDumortier J, Dharancy S, Cannesson A, Lassailly G, Rolland B, Pruvot FR, et al. Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. Am J Gastroenterol. 2015; 110: 1160 ‐ 1166.
dc.identifier.citedreferenceDiMartini A, Dew MA, Day N, Fitzgerald MG, Jones BL, DeVera ME, et al. Trajectories of alcohol consumption following liver transplantation. Am J Transplant 2010; 10: 2305 ‐ 2312.
dc.identifier.citedreferencePiano S, Marchioro L, Gola E, Rosi S, Morando F, Cavallin M, et al. Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available. Liver Transpl 2014; 20: 815 ‐ 822.
dc.identifier.citedreferenceFaure S, Herrero A, Jung B, Duny Y, Daures JP, Mura T, et al. Excessive alcohol consumption after liver transplantation impacts on long‐term survival, whatever the primary indication. J Hepatol 2012; 57: 306 ‐ 312.
dc.identifier.citedreferenceWells JT, Said A, Agni R, Tome S, Hughes S, Dureja P, et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl 2007; 13: 1728 ‐ 1735.
dc.identifier.citedreferenceSingal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 2012; 55: 1398 ‐ 1405.
dc.identifier.citedreferenceIm GY, Kim‐Schluger L, Shenoy A, Schubert E, Goel A, Friedman SL, et al. Early liver transplantation for severe alcoholic hepatitis in the United States—a single‐center experience. Am J Transplant 2016; 16: 841 ‐ 849.
dc.identifier.citedreferenceLee BP, Chen PH, Haugen C, Hernaez R, Gurakar A, Philosophe B, et al. Three‐year results of a pilot program in early liver transplantation for severe alcoholic hepatitis. Ann Surg 2017; 265: 20 ‐ 29.
dc.identifier.citedreferenceLee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology 2018; 155: 422 ‐ 430.
dc.identifier.citedreferenceLee BP, Vittinghoff E, Hsu C, Han H, Therapondos G, Fix OK, et al. Predicting low risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the sustained alcohol use post‐liver transplant score. Hepatology 2019; 69: 1477 ‐ 1487.
dc.identifier.citedreferenceThursz M, Allison M. Liver transplantation for alcoholic hepatitis: being consistent about where to set the bar. Liver Transpl 2018; 24: 733 ‐ 734.
dc.identifier.citedreferenceDureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol 2010; 52: 759 ‐ 764.
dc.identifier.citedreferencePuri P, Cholankeril G, Myint TY, Goel A, Sarin SK, Harper AM, et al. Early liver transplantation is a viable treatment option in severe acute alcoholic hepatitis. Alcohol Alcohol 2018; 53: 716 ‐ 718.
dc.identifier.citedreferenceBangaru S, Pedersen MR, MacConmara MP, Singal AG, Mufti AR. Survey of liver transplantation practices for severe acute alcoholic hepatitis. Liver Transpl 2018; 24: 1357 ‐ 1362.
dc.identifier.citedreferenceWinder GS, Mellinger J, Fontana RJ. Preventing drinking relapse in patients with alcoholic liver disease: your role is essential in preventing, detecting, and co‐managing alcoholic liver disease in inpatient and ambulatory settings. Curr Psychiatr 2015; 14: 22.
dc.identifier.citedreferenceMathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol 2012; 56 ( Suppl 1 ): S39 ‐ S45.
dc.identifier.citedreferenceEdmondson HA, Peters RL, Frankel HH, Borowsky S. The early stage of liver injury in the alcoholic. Medicine 1967; 46: 119 ‐ 129.
dc.identifier.citedreferenceGuirguis J, Chhatwal J, Dasarathy J, Rivas J, McMichael D, Nagy LE, et al. Clinical impact of alcohol‐associated cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. Alcohol Clin Exp Res 2015; 39: 2085 ‐ 2094.
dc.identifier.citedreferenceTapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ 2018; 362: k2817.
dc.identifier.citedreferenceCase A, Deaton A. Rising morbidity and mortality in midlife among white non‐Hispanic Americans in the 21st century. Proc Natl Acad Sci USA 2015; 112: 15078 ‐ 15083.
dc.identifier.citedreferencePeery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 2015; 149: 1731 ‐ 1741.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524 ‐ 530.
dc.identifier.citedreferenceBeste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001‐2013. Gastroenterology 2015; 149: 1471 ‐ 1482.
dc.identifier.citedreferenceMellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology 2018; 68: 872 ‐ 882.
dc.identifier.citedreferenceRehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013; 59: 160 ‐ 168.
dc.identifier.citedreferenceWorld Health Organization. Global Status Report on Alcohol and Health 2018. Geneva: WHO; 2018.
dc.identifier.citedreferenceGoldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017; 152: 1090 ‐ 1099.
dc.identifier.citedreferenceChirapongsathorn S, Krittanawong C, Enders FT, Pendegraft R, Mara KC, Borah BJ, et al. Incidence and cost analysis of hospital admission and 30‐day readmission among patients with cirrhosis. Hepatology Communications 2018; 2: 188 ‐ 198.
dc.identifier.citedreferenceRehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol‐use disorders. Lancet 2009; 373: 2223 ‐ 2233.
dc.identifier.citedreferenceJinjuvadia R, Liangpunsakul S. Translational research and evolving alcoholic hepatitis treatment consortium trends in alcoholic hepatitis‐related hospitalizations, financial burden, and mortality in the United States. J Clin Gastroenterol 2015; 49: 506 ‐ 511.
dc.identifier.citedreferencePang JX, Ross E, Borman MA, Zimmer S, Kaplan GG, Heitman SJ, et al. Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data. BMC Gastroenterol 2015; 15: 116.
dc.identifier.citedreferenceSandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: a nationwide population based cohort study. J Hepatol 2011; 54: 760 ‐ 764.
dc.identifier.citedreferenceSahlman P, Nissinen M, Pukkala E, Färkkilä M. Incidence, survival and cause‐specific mortality in alcoholic liver disease: a population‐based cohort study. Scand J Gastroenterol 2016; 51: 961 ‐ 966.
dc.identifier.citedreferenceAlavi M, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, et al. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study. J Hepatol 2018; 68: 393 ‐ 401.
dc.identifier.citedreferenceAssociation AP. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5®). Philadelphia, PA: American Psychiatric Association; 2013.
dc.identifier.citedreferenceGrant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM‐5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72: 757 ‐ 766.
dc.identifier.citedreferenceGrant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12‐month alcohol use, high‐risk drinking, and DSM‐IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017; 74: 911 ‐ 923.
dc.identifier.citedreferenceVaughn‐Sandler V, Sherman C, Aronsohn A, Volk ML. Consequences of perceived stigma among patients with cirrhosis. Dig Dis Sci 2014; 59: 681 ‐ 686.
dc.identifier.citedreferenceRies RK, Fiellin DA, Miller SC, Saitz R. The ASAM Principles of Addiction Medicine, 5th edn. Philadelphia, PA: Wolters Kluwer Health; 2014.
dc.identifier.citedreferenceNIAAA. Helping patients who drink too much: a clinician’s guide. https://www.niaaa.nih.gov/guide. Accessed January 4, 2019.
dc.identifier.citedreferenceUS Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320: 1899 ‐ 1909.
dc.identifier.citedreferenceSaunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction 1993; 88: 791 ‐ 804.
dc.identifier.citedreferenceConigrave KM, Saunders JB, Reznik RB. Predictive capacity of the AUDIT questionnaire for alcohol‐associated harm. Addiction 1995; 90: 1479 ‐ 1485.
dc.identifier.citedreferenceBush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT‐C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158: 1789 ‐ 1795.
dc.identifier.citedreferenceBradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT‐C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31: 1208 ‐ 1217.
dc.identifier.citedreferenceNIAAA. https://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/niaaa-clinicians-guide-online-training. Accessed August 1, 2019.
dc.identifier.citedreferenceSheron N, Moore M, O’Brien W, Harris S, Roderick P. Feasibility of detection and intervention for alcohol‐associated liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS). Br J Gen Pract 2013; 63: e698 ‐ e705.
dc.identifier.citedreferenceWestwood G, Meredith P, Atkins S, Greengross P, Schmidt PE, Aspinall RJ. Universal screening for alcohol misuse in acute medical admissions is feasible and identifies patients at high risk of liver disease. J Hepatol 2017; 67: 559 ‐ 567.
dc.identifier.citedreferenceDonnadieu‐Rigole H, Olive L, Nalpas B, Winter A, Ursic‐Bedoya J, Faure S, et al. Follow‐up of alcohol consumption after liver transplantation: interest of an addiction team? Alcohol Clin Exp Res 2017; 41: 165 ‐ 170.
dc.identifier.citedreferenceAu DH, Kivlahan DR, Bryson CL, Blough D, Bradley KA. Alcohol screening scores and risk of hospitalizations for GI conditions in men. Alcohol Clin Exp Res 2007; 31: 443 ‐ 451.
dc.identifier.citedreferenceJarvis M, Williams J, Hurford M, Lindsay D, Lincoln P, Giles L, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med 2017; 11: 163 ‐ 173.
dc.identifier.citedreferenceThe American Psychiatric Association Practice Guideline for the pharmacological treatment of patients with alcohol use disorder. https://doi.org/10.1176/appi.books.9781615371969. Accessed January 4, 2019.
dc.identifier.citedreferenceDiMartini A. Alcohol Abuse and Liver Disease. John Wiley & Sons; 2016.
dc.identifier.citedreferenceLitten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 2010; 34: 955 ‐ 967.
dc.identifier.citedreferenceConigrave KM, Davies P, Haber P, Whitfield JB. Traditional markers of excessive alcohol use. Addiction 2003; 98 ( Suppl 2 ): 31 ‐ 43.
dc.identifier.citedreferenceAnton RF, Lieber C, Tabakoff B. Carbohydrate‐deficient transferrin and gamma‐glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study. Alcohol Clin Exp Res 2002; 26: 1215 ‐ 1222.
dc.identifier.citedreferenceBerlakovich GA, Soliman T, Freundorfer E, Windhager T, Bodingbauer M, Wamser P, et al. Pretransplant screening of sobriety with carbohydrate‐deficient transferrin in patients suffering from alcoholic cirrhosis. Transpl Int 2004; 17: 617 ‐ 621.
dc.identifier.citedreferenceDiMartini A, Day N, Lane T, Beisler AT, Dew MA, Anton R. Carbohydrate deficient transferrin in abstaining patients with end‐stage liver disease. Alcohol Clin Exp Res 2001; 25: 1729 ‐ 1733.
dc.identifier.citedreferenceStewart SH, Reuben A, Anton RF. Relationship of abnormal chromatographic pattern for carbohydrate‐deficient transferrin with severe liver disease. Alcohol Alcohol 2017; 52: 24 ‐ 28.
dc.identifier.citedreferenceBerlakovich GA, Windhager T, Freundorfer E, Lesch OM, Steininger R, Mühlbacher F. Carbohydrate deficient transferrin for detection of alcohol relapse after orthotopic liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67: 1231 ‐ 1235.
dc.identifier.citedreferenceAllen JP, Wurst FM, Thon N, Litten RZ. Assessing the drinking status of liver transplant patients with alcoholic liver disease. Liver Transpl 2013; 19: 369 ‐ 376.
dc.identifier.citedreferenceWalsham NE, Sherwood RA. Ethyl glucuronide. Ann Clin Biochem 2012; 49: 110 ‐ 117.
dc.identifier.citedreferenceStaufer K, Andresen H, Vettorazzi E, Tobias N, Nashan B, Sterneck M. Urinary ethyl glucuronide as a novel screening tool in patients pre‐ and post‐liver transplantation improves detection of alcohol consumption. Hepatology 2011; 54: 1640 ‐ 1649.
dc.identifier.citedreferenceStewart SH, Koch DG, Burgess DM, Willner IR, Reuben A. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. Alcohol Clin Exp Res 2013; 37: 150 ‐ 155.
dc.identifier.citedreferenceAndresen‐Streichert H, Beres Y, Weinmann W, Schröck A, Müller A, Skopp G, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int 2017; 30: 611 ‐ 620.
dc.identifier.citedreferenceNguyen VL, Haber PS, Seth D. Applications and challenges for the use of phosphatidylethanol testing in liver disease patients (mini review). Alcohol Clin Exp Res 2018; 42: 238 ‐ 243.
dc.identifier.citedreferenceGnann H, Weinmann W, Thierauf A. Formation of phosphatidylethanol and its subsequent elimination during an extensive drinking experiment over 5 days. Alcohol Clin Exp Res 2012; 36: 1507 ‐ 1511.
dc.identifier.citedreferenceSchröck A, Wurst FM, Thon N, Weinmann W. Assessing phosphatidylethanol (PEth) levels reflecting different drinking habits in comparison to the alcohol use disorders identification test ‐ C (AUDIT‐C). Drug Alcohol Depend 2017; 178: 80 ‐ 86.
dc.identifier.citedreferenceWurst FM, Thon N, Aradottir S, Hartmann S, Wiesbeck GA, Lesch O, et al. Phosphatidylethanol: normalization during detoxification, gender aspects and correlation with other biomarkers and self‐reports. Addict Biol 2010; 15: 88 ‐ 95.
dc.identifier.citedreferenceViel G, Boscolo‐Berto R, Cecchetto G, Fais P, Nalesso A, Ferrara SD. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta‐analysis. Int J Mol Sci 2012; 13: 14788 ‐ 14812.
dc.identifier.citedreferenceStewart SH, Reuben A, Brzezinski WA, Koch DG, Basile J, Randall PK, et al. Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol Alcohol 2009; 44: 464 ‐ 467.
dc.identifier.citedreferenceSimon TW. Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model. Regul Toxicol Pharmacol 2018; 94: 163 ‐ 171.
dc.identifier.citedreferenceStewart SH, Law TL, Randall PK, Newman R. Phosphatidylethanol and alcohol consumption in reproductive age women. Alcohol Clin Exp Res 2010; 34: 488 ‐ 492.
dc.identifier.citedreferenceStewart SH, Koch DG, Willner IR, Anton RF, Reuben A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res 2014; 38: 1706 ‐ 1711.
dc.identifier.citedreferenceMiller WR, Rollnick S. Motivational Interviewing, 3rd edn. New York: Guilford Press; 2012.
dc.identifier.citedreferenceNIAAA. NIAAA alcohol treatment navigator. https://alcoholtreatment.niaaa.nih.gov. Accessed January 4, 2019.
dc.identifier.citedreferenceKhan A, Tansel A, White DL, Kayani WT, Bano S, Lindsay J, et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. Clin Gastroenterol Hepatol 2016; 14: 191 ‐ 202.
dc.identifier.citedreferenceWillenbring ML, Olson DH. A randomized trial of integrated outpatient treatment for medically ill alcoholic men. Arch Intern Med 1999; 159: 1946 ‐ 1952.
dc.identifier.citedreferenceWeinrieb RM, Van Horn DHA, Lynch KG, Lucey MR. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl 2011; 17: 539 ‐ 547.
dc.identifier.citedreferenceKuchipudi V, Hobein K, Flickinger A, Iber FL. Failure of a 2‐hour motivational intervention to alter recurrent drinking behavior in alcoholics with gastrointestinal disease. J Stud Alcohol 1990; 51: 356 ‐ 360.
dc.identifier.citedreferenceDieperink E, Fuller B, Isenhart C, McMaken K, Lenox R, Pocha C, et al. Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial. Addiction 2014; 109: 1869 ‐ 1877.
dc.identifier.citedreferenceDieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML. Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics 2010; 51: 149 ‐ 156.
dc.identifier.citedreferenceProeschold‐Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, et al. An integrated alcohol abuse and medical treatment model for patients with hepatitis C. Dig Dis Sci 2012; 57: 1083 ‐ 1091.
dc.identifier.citedreferenceDrumright LN, Hagan H, Thomas DL, Latka MH, Golub ET, Garfein RS, et al. Predictors and effects of alcohol use on liver function among young HCV‐infected injection drug users in a behavioral intervention. J Hepatol 2011; 55: 45 ‐ 52.
dc.identifier.citedreferenceKlimas J, Tobin H, Field CA, O’Gorman CS, Glynn LG, Keenan E, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev 2014; 12: CD009269.
dc.identifier.citedreferenceAddolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol 2016; 65: 618 ‐ 630.
dc.identifier.citedreferenceJohnson BA, Ait‐Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677 ‐ 1685.
dc.identifier.citedreferenceJohnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641 ‐ 1651.
dc.identifier.citedreferenceJohnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000; 284: 963 ‐ 971.
dc.identifier.citedreferencede Bejczy A, Löf E, Walther L, Guterstam J, Hammarberg A, Asanovska G, et al. Varenicline for treatment of alcohol dependence: a randomized, placebo‐controlled trial. Alcohol Clin Exp Res 2015; 39: 2189 ‐ 2199.
dc.identifier.citedreferenceLeggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav 2012; 37: 561 ‐ 564.
dc.identifier.citedreferenceYamini D, Lee SH, Avanesyan A, Walter M, Runyon B. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol 2014; 49: 453 ‐ 456.
dc.identifier.citedreferenceAddolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol‐dependent patients with liver cirrhosis: randomised, double‐blind controlled study. Lancet 2007; 370: 1915 ‐ 1922.
dc.identifier.citedreferenceRehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, Roerecke M. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta‐analysis. Drug Alcohol Rev 2010; 29: 437 ‐ 445.
dc.identifier.citedreferenceOffice of Disease Prevention and Health Promotion. Dietary guidelines for Americans 2015–2020. 8th ed. https://health.gov/dietaryguidelines/2015/guidelines/. Accessed January 4, 2019.
dc.identifier.citedreferenceNIAAA. Drinking levels defined. https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking. Accessed January 4, 2019.
dc.identifier.citedreferenceSAMHSA. Alcohol use: facts and resources. https://www.samhsa.gov/sites/default/files/alcohol-use-facts-resources-fact-sheet.pdf. Accessed January 4, 2019.
dc.identifier.citedreferenceWood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual‐participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018; 391: 1513 ‐ 1523.
dc.identifier.citedreferenceGBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018; 392: 1015 ‐ 1035.
dc.identifier.citedreferenceSeitz HK, Bataller R, Cortez‐Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers 2018; 4: 16.
dc.identifier.citedreferenceSavolainen VT, Liesto K, Mannikko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res 1993; 17: 1112 ‐ 1117.
dc.identifier.citedreferenceBellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845 ‐ 850.
dc.identifier.citedreferenceBecker U, Deis A, Sorensen TI, Gronbaek M, Borch‐Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23: 1025 ‐ 1029.
dc.identifier.citedreferenceBecker U, Grønbaek M, Johansen D, Sørensen TI. Lower risk for alcohol‐induced cirrhosis in wine drinkers. Hepatology 2002; 35: 868 ‐ 875.
dc.identifier.citedreferenceAskgaard G, Grønbæk M, Kjær MS, Tjønneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol 2015; 62: 1061 ‐ 1067.
dc.identifier.citedreferenceDam MK, Flensborg‐Madsen T, Eliasen M, Becker U, Tolstrup JS. Smoking and risk of liver cirrhosis: a population‐based cohort study. Scand J Gastroenterol 2013; 48: 585 ‐ 591.
dc.identifier.citedreferenceÅberg F, Helenius‐Hietala J, Puukka P, Jula A. Binge drinking and the risk of liver events: a population‐based cohort study. Liver Int 2017; 37: 1373 ‐ 1381.
dc.identifier.citedreferenceKlatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992; 136: 1248 ‐ 1257.
dc.identifier.citedreferenceStroffolini T, Cotticelli G, Medda E, Niosi M, Del Vecchio‐Blanco C, Addolorato G, et al. Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int 2010; 30s: 867 ‐ 870.
dc.identifier.citedreferenceWadhawan M, Anand AC. Coffee and liver disease. J Clin Exp Hepatol 2016; 6: 40 ‐ 46.
dc.identifier.citedreferenceKennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta‐analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther 2016; 43: 562 ‐ 574.
dc.identifier.citedreferenceLiangpunsakul S, Beaudoin JJ, Shah VH, Puri P, Sanyal AJ, Kamath PS, et al. Interaction between the patatin‐like phospholipase domain‐containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. Hepatol Commun 2017; 2: 29 ‐ 34.
dc.identifier.citedreferenceEdenberg HJ, Foroud T. Genetics and alcoholism. Nat Rev Gastroenterol Hepatol 2013; 10: 487 ‐ 494.
dc.identifier.citedreferenceReed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ‐specific endpoints of alcoholism. Alcohol Clin Exp Res 1996; 20: 1528 ‐ 1533.
dc.identifier.citedreferenceCrabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol‐associated pathology. Proc Nutr Soc 2004; 63: 49 ‐ 63.
dc.identifier.citedreferenceZeng T, Guo FF, Zhang CL, Song FY, Zhao XL, Xie KQ. Roles of cytochrome P4502E1 gene polymorphisms and the risks of alcoholic liver disease: a meta‐analysis. PLoS One 2013; 8: e54188.
dc.identifier.citedreferenceStinson FS, Grant BF, Dufour MC. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 2001; 25: 1181 ‐ 1187.
dc.identifier.citedreferenceLevy R, Catana AM, Durbin‐Johnson B, Halsted CH, Medici V. Ethnic differences in presentation and severity of alcoholic liver disease. Alcohol Clin Exp Res 2015; 39: 566 ‐ 574.
dc.identifier.citedreferenceSalameh H, Raff E, Erwin A, Seth D, Nischalke HD, Falleti E, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol 2015; 110: 846 ‐ 856.
dc.identifier.citedreferenceBuch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, et al. A genome‐wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol‐associated cirrhosis. Nat Genet 2015; 47: 1443 ‐ 1448.
dc.identifier.citedreferenceAtkinson SR, Way MJ, McQuillin A, Morgan MY, Thursz MR. Homozygosity for rs738409: G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. J Hepatol 2017; 67: 120 ‐ 127.
dc.identifier.citedreferenceBeaudoin JJ, Long N, Liangpunsakul S, Puri P. Kamath PS, Shah V; TREAT Consortium. An exploratory genome‐wide analysis of genetic risk for alcoholic hepatitis. Scand J Gastroenterol 2017; 52: 1263 ‐ 1269.
dc.identifier.citedreferenceStickel F, Moreno C, Hampe J, Morgan MY. The genetics of alcohol dependence and alcohol‐associated liver disease. J Hepatol 2017; 66: 195 ‐ 211.
dc.identifier.citedreferenceStickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol‐associated cirrhosis. Am J Gastroenterol 2018; 113: 1475 ‐ 1483.
dc.identifier.citedreferenceAbul‐Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein‐truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018; 378: 1096 ‐ 1106.
dc.identifier.citedreferenceAjmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology 2017; 65: 2090 ‐ 2099.
dc.identifier.citedreferenceÅberg F, Helenius‐Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 2018; 67: 2141 ‐ 2149.
dc.identifier.citedreferenceSchwarzinger M, Baillot S, Yazdanpanah Y, Rehm J, Mallet V. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008–2013: a nationwide retrospective cohort study. J Hepatol 2017; 67: 454 ‐ 461.
dc.identifier.citedreferenceFletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122: 281 ‐ 289.
dc.identifier.citedreferenceNational Center on Addiction and Substance Abuse at Columbia University. Missed Opportunity: National Survey of Primary Care Physicians and Patients on Substance Abuse. April 2000. http://www.casacolumbia.org/addiction-research/reports/national-survey-primary-care-physicians-patients-substance-abuse. Accessed January 4, 2019.
dc.identifier.citedreferenceHatton J, Burton A, Nash H, Munn E, Burgoyne L, Sheron N. Drinking patterns, dependency and life‐time drinking history in alcohol‐associated liver disease. Addiction 2009; 104: 587 ‐ 592.
dc.identifier.citedreferenceLucey MR, Connor JT, Boyer TD, Henderson JM, Rikkers LF; DIVERT Study Group. Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function. Am J Gastroenterol 2008; 103: 1698 ‐ 1706.
dc.identifier.citedreferenceWhitfield JB, Masson S, Liangpunsakul S, Hyman J, Mueller S, Aithal G, et al. Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol 2018; 66: 1 ‐ 7.
dc.identifier.citedreferenceTapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med 2017; 7 ( 377 ): 2296 ‐ 2297.
dc.identifier.citedreferenceReeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011; 34: 729 ‐ 749.
dc.identifier.citedreferenceBaptista A, Bianchi L, de Groote J. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981; 1: 707 ‐ 711.
dc.identifier.citedreferenceIm GY, Lucey MR. Practical concerns and controversies in the management of alcoholic hepatitis. Gastroenterol Hepatol (N Y) 2016; 12: 478 ‐ 489.
dc.identifier.citedreferenceCrabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology 2016; 150: 785 ‐ 790.
dc.identifier.citedreferenceBissonnette J, Altamirano J, Devue C, Roux O, Payancé A, Lebrec D, et al. A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology 2007; 66: 555 ‐ 563.
dc.identifier.citedreferenceHanouneh IA, Zein NN, Cikach F, Dababneh L, Grove D, Alkhouri N, et al. The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. Clin Gastroenterol Hepatol 2014; 12: 516 ‐ 523.
dc.identifier.citedreferenceGelsi E, Dainese R, Truchi R, Mariné‐Barjoan E, Anty R, Autuori M, et al. Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients. Alcohol Clin Exp Res 2011; 35: 566 ‐ 570.
dc.identifier.citedreferenceThiele M, Detlefsen S, Sevelsted Møller L, Madsen BS, Fuglsang Hansen J, Fialla AD, et al. Transient and 2‐dimensional shear‐wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis. Gastroenterology 2016; 150: 123 ‐ 133.
dc.identifier.citedreferenceThiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 2018; 154: 1369 ‐ 1379.
dc.identifier.citedreferenceLucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758 ‐ 2769.
dc.identifier.citedreferenceMaddrey WC, Boitnott JK, Bedine MS, Weber FL Jr., Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193 ‐ 199.
dc.identifier.citedreferenceForrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 1743 ‐ 1746.
dc.identifier.citedreferenceDunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353 ‐ 358.
dc.identifier.citedreferenceDominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103: 2747 ‐ 2756.
dc.identifier.citedreferenceMerion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003; 9: 12 ‐ 18.
dc.identifier.citedreferenceLouvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348 ‐ 1354.
dc.identifier.citedreferenceGarcia‐Saenz‐de‐Sicilia M, Duvoor C, Altamirano J, Chavez‐Araujo R, Prado V, de Lourdes Candolo‐Martinelli A, et al. A day‐4 Lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis. Am J Gastroenterol 2017; 112: 306 ‐ 315.
dc.identifier.citedreferenceLouvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O’Grady J, et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. Gastroenterology 2015; 149: 398 ‐ 406.
dc.identifier.citedreferenceAltamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte‐Rojo A, Louvet A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146: 1231 ‐ 1239.
dc.identifier.citedreferenceHorvath B, Allende D, Xie H, Guirguis J, Jeung J, Lapinski J, et al. Interobserver variability in scoring liver biopsies with a diagnosis of alcoholic hepatitis. Alcohol Clin Exp Res 2017; 41: 1568 ‐ 1573.
dc.identifier.citedreferenceTrépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, Marot A, et al. Combination of gene expression signature and Model for End‐Stage Liver Disease score predicts survival of patients with severe alcoholic hepatitis. Gastroenterology 2018; 154: 965 ‐ 975.
dc.identifier.citedreferenceAltamirano J, Fagundes C, Dominguez M, García E, Michelena J, Cárdenas A, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2012; 10: 65 ‐ 71.
dc.identifier.citedreferenceSujan R, Cruz‐Lemini M, Altamirano J, Simonetto D, Maiwall R, Axley P, et al. A validated score predicts acute kidney injury and survival in patients with alcoholic hepatitis: a multicentric international prospective cohort study. Liver Transpl 2018; 24: 1655 ‐ 1664.
dc.identifier.citedreferenceMichelena J, Altamirano J, Abraldes JG, Affò S, Morales‐Ibanez O, Sancho‐Bru P, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 2015; 62: 762 ‐ 772.
dc.identifier.citedreferenceLouvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva‐Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137: 541 ‐ 548.
dc.identifier.citedreferenceVergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection‐related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology 2017; 152: 1068 ‐ 1077.
dc.identifier.citedreferenceLouvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology 2017; 66: 1464 ‐ 1473.
dc.identifier.citedreferenceAltamirano J, López‐Pelayo H, Michelena J, Jones PD, Ortega L, Ginès P, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long‐term survival. Hepatology 2017; 66: 1842 ‐ 1853.
dc.identifier.citedreferenceThursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP; STOPAH  Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372: 1619 ‐ 1628.
dc.identifier.citedreferenceVerrill C, Markham H, Templeton A, Carr NJ, Sheron N, et al. Alcohol‐associated cirrhosis—early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009; 104: 768 ‐ 774.
dc.identifier.citedreferencePotts JR, Goubet S, Heneghan MA, Verma S. Determinants of long‐term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 38: 584 ‐ 595.
dc.identifier.citedreferenceMendenhall CL, Tosch T, Weesner RE, Garcia‐Pont P, Goldberg SJ, Kiernan T, et al. VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein‐calorie malnutrition. Am J Clin Nutr 1986; 43: 213 ‐ 218.
dc.identifier.citedreferencePlauth M, Cabré E, Riggio O, Assis‐Camilo M, Pirlich M, Kondrup J, et al.; DGEM (German Society for Nutritional Medicine). ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25: 285 ‐ 294.
dc.identifier.citedreferenceAntar R, Wong P, Ghali P. A meta‐analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol 2012; 26: 463 ‐ 467.
dc.identifier.citedreferenceFialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta‐analysis. Liver Int 2015; 35: 2072 ‐ 2078.
dc.identifier.citedreferenceMoreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology 2016; 150: 903 ‐ 910.
dc.identifier.citedreferenceBjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Antioxidant supplements for liver diseases. Cochrane Database Syst Rev 2011; 16: CD007749.
dc.identifier.citedreferencePhillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis—a randomised clinical trial. J Hepatol 2006; 44: 784 ‐ 790.
dc.identifier.citedreferenceMcClain C, Vatsalya V, Cave M. Role of zinc in the development/progression of alcoholic liver disease. Curr Treat Options Gastroenterol 2017; 15: 285 ‐ 295.
dc.identifier.citedreferenceDupont B, Dao T, Joubert C, Dupont‐Lucas C, Gloro R, Nguyen‐Khac E, et al. Randomised clinical trial: enteral nutrition does not improve the long‐term outcome of alcoholic cirrhotic patients with jaundice. Aliment Pharmacol Ther 2012; 35: 1166 ‐ 1174.
dc.identifier.citedreferenceLieber SR, Rice JP, Lucey MR, Bataller R. Controversies in clinical trials for alcoholic hepatitis. J Hepatol 2018; 68: 586 ‐ 592.
dc.identifier.citedreferenceRambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato‐Biliary Group systematic review with meta‐analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167 ‐ 1178.
dc.identifier.citedreferenceChristensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta‐analysis adjusting for confounding variables. Gut 1995; 37: 113 ‐ 118.
dc.identifier.citedreferencePavlov CS, Varganova DL, Casazza G, Tsochatzis E, Nikolova D, Gluud C. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev 2017; 11: CD001511.
dc.identifier.citedreferenceMathurin P, Mendenhall CL, Carithers RL Jr., Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short‐term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480 ‐ 487.
dc.identifier.citedreferenceMathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short‐term survival in patients with severe alcoholic hepatitis: meta‐analysis of individual patient data. Gut 2011; 60: 255 ‐ 260.
dc.identifier.citedreferenceLouvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo‐a meta‐analysis of individual data from controlled trials. Gastroenterology 2018; 155: 458 ‐ 468.
dc.identifier.citedreferenceO’Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Hepatology 2010; 51: 307 ‐ 328.
dc.identifier.citedreferenceMendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995; 19: 635 ‐ 641.
dc.identifier.citedreferenceClinicalTrials.gov. Efficacy of antibiotic therapy in severe alcoholic hepatitis treated with prednisolone (AntibioCor). https://clinicaltrials.gov/ct2/show/NCT02281929. Accessed January 6, 2019.
dc.identifier.citedreferenceMathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790 ‐ 1800.
dc.identifier.citedreferenceGustot T, Maillart E, Bocci M, Surin R, Trépo E, Degré D, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol 2014; 60: 267 ‐ 274.
dc.identifier.citedreferenceParker R, Im G, Jones F, Hernández OP, Nahas J, Kumar A, et al. Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study. J Gastroenterol 2017; 52: 1192 ‐ 1200.
dc.identifier.citedreferenceRudler M, Mouri S, Charlotte F, Lebray P, Capocci R, Benosman H, et al. Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding. J Hepatol 2015; 62: 816 ‐ 821.
dc.identifier.citedreferenceNguyen‐Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365: 1781 ‐ 1789.
dc.identifier.citedreferencePrescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N‐acetylcysteine. Lancet 1977; 2: 432 ‐ 434.
dc.identifier.citedreferenceLee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N‐acetylcysteine improves transplant‐free survival in early stage non‐acetaminophen acute liver failure. Gastroenterology 2009; 137: 856 ‐ 864.
dc.identifier.citedreferenceSingh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta‐analysis. Gastroenterology 2015; 149: 958 ‐ 970.
dc.identifier.citedreferenceSingh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014; 109: 1417 ‐ 1423.
dc.identifier.citedreferenceMoreau R, Rautou PE. G‐CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol 2014; 109: 1424 ‐ 1426.
dc.identifier.citedreferencePhilips CA, Pande A, Shasthry SM, Jamwal KD, Khillan V, Chandel SS, et al. Healthy donor fecal microbiota transplantation in steroid‐ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol 2017; 15: 600 ‐ 602.
dc.identifier.citedreferenceHiguera‐dela Tijera F, Servín‐Caamaño AI, Serralde‐Zúñiga AE, Cruz‐Herrera J, Pérez‐Torres E, Abdo‐Francis JM, et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol 2015; 21: 4975 ‐ 4985.
dc.identifier.citedreferenceAkriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology 2000; 119: 1637 ‐ 1648.
dc.identifier.citedreferenceMathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013; 310: 1033 ‐ 1041.
dc.identifier.citedreferenceLouvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thévenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non‐responders to corticosteroids. J Hepatol 2008; 48: 465 ‐ 470.
dc.identifier.citedreferenceNaveau S, Chollet‐Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390 ‐ 1397.
dc.identifier.citedreferenceBoetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953 ‐ 1960.
dc.identifier.citedreferenceThompson J, Jones N, Al‐Khafaji A, Malik S, Reich D, Munoz S, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl 2018; 24: 380 ‐ 393.
dc.identifier.citedreferenceRambaldi A, Gluud C. S‐adenosyl‐L‐methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2001; 4: CD002235.
dc.identifier.citedreferenceMezey E, Potter JJ, Rennie‐Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004; 40: 40 ‐ 46.
dc.identifier.citedreferenceTrinchet JC, Balkau B, Poupon RE, Heintzmann F, Callard P, Gotheil C, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992; 15: 76 ‐ 81.
dc.identifier.citedreferenceBonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short‐term effects on liver function. Am J Gastroenterol 1991; 86: 1200 ‐ 1208.
dc.identifier.citedreferenceFede G, Germani G, Gluud C, Gurusamy KS, Burroughs AK. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2011; 6: CD002800.
dc.identifier.citedreferenceSingal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol 2014; 12: 555 ‐ 564.
dc.identifier.citedreferenceSzabo G. Clinical Trial Design for Alcoholic Hepatitis. Semin Liver Dis 2017; 37: 332 ‐ 342.
dc.identifier.citedreferenceNoureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol 2018; 113: 1649 ‐ 1659.
dc.identifier.citedreferenceCholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2018; 16: 1356 ‐ 1358.
dc.identifier.citedreferenceLucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011; 17: 751 ‐ 759.
dc.identifier.citedreferenceFleming MF, Smith MJ, Oslakovic E, Lucey MR, Vue JX, Al‐Saden P, et al. Phosphatidylethanol (PEth) detects moderate to heavy alcohol use in liver transplant recipients. Alcohol Clin Exp Res 2017; 41: 857 ‐ 862.
dc.identifier.citedreferenceNational Institutes of Health Consensus Development Conference on Liver Transplantation. Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and the National Institutes of Health Office of Medical Applications of Research. Hepatology 1984; 4 ( Suppl 1 ): 1S ‐ 110S.
dc.identifier.citedreferenceWong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148: 547 ‐ 555.
dc.identifier.citedreferenceLucey MR. Liver transplantation for alcoholic liver disease. Nat Rev Gastroenterol Hepatol 2014; 11: 300 ‐ 307.
dc.identifier.citedreferenceVolk ML, Biggins SW, Huang MA, Argo CK, Fontana RJ, Anspach RR. Decision making in liver transplant selection committees: a multicenter study. Ann Intern Med 2011; 155: 503 ‐ 508.
dc.identifier.citedreferenceMoss AH, Siegler M. Should alcoholics compete equally for liver transplantation? JAMA 1991; 265: 1295 ‐ 1298.
dc.identifier.citedreferenceVeldt BJ, Lainé F, Guillygomarc’h A, Lauvin L, Boudjema K, Messner M, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93 ‐ 98.
dc.identifier.citedreferenceVanlemmens C, Di Martino V, Milan C, Messner M, Minello A, Duvoux C, et al. Immediate listing for liver transplantation versus standard care for Child‐Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med 2009; 150: 153 ‐ 161.
dc.identifier.citedreferenceNagai S, Chau LC, Schilke RE, Safwan M, Rizzari M, Collins K, et al. Effects of allocating livers for transplantation based on Model for End‐Stage Liver Disease‐Sodium scores on patient outcomes. Gastroenterology 2018; 155: 1451 ‐ 1462.
dc.identifier.citedreferenceBeresford TP, Lucey MR. Towards standardizing the alcoholism evaluation of potential liver transplant recipients. Alcohol Alcohol 2018; 53: 135 ‐ 144.
dc.identifier.citedreferenceEverhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg 1997; 3: 220 ‐ 226.
dc.identifier.citedreferenceBeresford TP. Transplantation and the Alcoholic Patient. Lucey MR, Merion RM, Beresford TP, eds. Cambridge, U.K: Cambridge University Press; 1994: 29 ‐ 49.
dc.identifier.citedreferenceLucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Disease. Liver Transpl Surg 1997; 3: 628 ‐ 637.
dc.identifier.citedreferenceLeong J, Im GY. Evaluation and selection of the patient with alcoholic liver disease for liver transplant. Clin Liver Dis 2012; 16: 851 ‐ 863.
dc.identifier.citedreferenceYates WR, Martin M, LaBrecque D, Hillebrand D, Voigt M, Pfab D. A model to examine the validity of the 6‐month abstinence criterion for liver transplantation. Alcohol Clin Exp Res 1998; 22: 513 ‐ 517.
dc.identifier.citedreferenceMathurin P, Lucey MR. Alcohol, liver disease, and transplantation: shifting attitudes and new understanding leads to changes in practice. Curr Opin Organ Transplant 2018; 23: 175 ‐ 179.
dc.identifier.citedreferenceMartin P, DiMartini A, Feng S, Brown R Jr., Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144 ‐ 1165.
dc.identifier.citedreferenceRodrigue JR, Hanto DW, Curry MP. The Alcohol Relapse Risk Assessment: a scoring system to predict the risk of relapse to any alcohol use after liver transplant. Prog Transplant 2013; 23: 310 ‐ 318.
dc.identifier.citedreferenceMaldonado JR, Dubois HC, David EE, Sher Y, Lolak S, Dyal J, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre‐transplant candidates. Psychosomatics 2012; 53: 123 ‐ 132.
dc.identifier.citedreferenceBeresford TP, Turcotte JG, Merion R, Burtch G, Blow FC, Campbell D, et al. A rational approach to liver transplantation for the alcoholic. Psychosomatics 1990; 31: 241 ‐ 254.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep30866_am.pdf
Size:
1.223MB
Format:
PDF
View/Open
Name:
hep30866.pdf
Size:
733.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.